The novel complement C3 inhibitor pegcetacoplan is significantly better at improving haemoglobin as well as other key clinical outcomes at week 16 versus the current standard of care, eculizumab, in patients with paroxysmal nocturnal haemoglobinuria (PNH).
Prof. Peter Hillmen (St James’s University Hospital, UK) presented the findings from the phase 3 PEGASUS trial [1]. Preliminary data from the phase 1b PHAROAH and PADDOCK trials provided proof-of-principle that pegcetacoplan could improve lactate dehydrogenase and haemoglobin levels in patients who had experienced a suboptimal response to eculizumab, and in eculizumab-naïve patients, respectively.
In PEGASUS, 80 adult PNH patients completed a 4-week run-in period with pegcetacoplan plus eculizumab before being randomised to 1,080 mg of subcutaneous pegcetacoplan twice weekly (n=41) or continued eculizumab (n=39). The primary endpoint of PEGASUS was the change in haemoglobin level from baseline to week 16. Key secondary endpoints included transfusion avoidance, reticulocyte counts, lactate dehydrogenase levels, Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-f) score, and safety.
PEGASUS’ primary efficacy endpoint was met. At week 16, patients in the pegcetacoplan arm had improved their adjusted mean haemoglobin levels from a baseline level of 8.7 g/dL by 3.84 g/dL, 53% higher than the eculizumab arm (95% CI 2.33-5.34; P<0.0001). In patients with low or no transfusion requirements, pegcetacoplan-treated patients (n=20) had an adjusted mean haemoglobin increase of 2.97 g/dL versus eculizumab-treated patients (n=16) who had a mean change of -0.01 g/dL from the 8.9 g/dL baseline. However, the difference between the treatment arms was more evident in patients with high transfusion requirements, where pegcetacoplan-treated patients (n=21) had an adjusted mean haemoglobin increase of 2.11 g/dL versus eculizumab-treated patients (n=23) who had a mean change of -4.02 g/dL from the 8.5 g/dL baseline.
The secondary endpoint of transfusion avoidance was achieved in 85% of patients (n=35) with pegcetacoplan versus 15% of patients (n=6) with eculizumab, with an adjusted risk difference of 63% (95% CI 48-77). Reticulocyte counts decreased with pegcetacoplan and increased with eculizumab, translating to an adjusted risk difference of -164 (95% CI -189.9 to -137.3). Lactate dehydrogenase levels were not significantly different between the arms, changing by -15 (42.7) in the pegcetacoplan arm and -10 (71.0) U/L in the eculizumab arm (95% CI -181.3 to 172.0). The FACIT-f assessment score increased with pegcetacoplan (9.2 [1.61]) and decreased with eculizumab (-2.7 [2.82]), although noninferiority was not evaluated due to the prespecified hierarchical testing.
The safety profile of pegcetacoplan was comparable with eculizumab, with adverse events being reported in 87.8% in the pegcetacoplan arm versus 87.2% in the eculizumab arm. The rate of serious adverse events was 17.1% and 15.4%, respectively. Treatment discontinuation due to haemolysis occurred in 9.8% of patients in the pegcetacoplan arm and 23.1% of patients in the eculizumab arm.
“PEGASUS is the first randomised phase 3 trial of a proximal C3 inhibitor and shows a rapid and sustained improvement in haemoglobin, a reduction in ongoing breakdown of blood cells, a marked reduction in blood transfusions, and a marked improvement in fatigue,” concluded Prof. Hillmen.
-
- Hillmen P, et al. Results of the PEGASUS phase III randomized trial demonstrating superiority of the c3 inhibitor, pegcetacoplan, compared to eculizumab in patients with paroxysmal nocturnal haemoglobinuria. EHA25 Virtual, 11-21 June 2020, Abstract S192.
Posted on
« Mitapivat, a pyruvate kinase-R activator, in SCD is safe with early efficacy results Next Article
Endothelial damage in COVID-19 »
Table of Contents: EHA 2020
Featured articles
Myeloid
VIALE-A: newly diagnosed chemo-ineligible AML
DEC10-VEN superior to intensive chemotherapy in high-risk AML
Magrolimab plus azacitidine: good ORR in MDS/AML
Asciminib monotherapy in Ph+ CML: major molecular responses
CML TKI interruption: Swedish registry results
Patients with lower-risk MDS benefit from imetelstat
Better outcomes adding enasidenib to azacitidine in mIDH2-AML
Lymphoid
PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
Promising first-in-human trial of epcoritamab in B-NHL
Two trials: acalabrutinib in CLL
Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia
Deep responses in R/R CLL with venetoclax monotherapy
MRD assessment post-CAR-T predicts ALL allo-HSCT bridging
Plasma Cell Dyscrasias
Daratumumab for light-chain amyloidosis
Isatuximab triplet improves PFS in R/R MM
Initial results from CAR-T cell therapy in MM: KarMMa
Graft-Versus-Host Disease
GRAVITAS-301: improved complete aGVDH response
Ruxolitinib improves steroid-refractory aGVHD across subtypes
Benign Haematology
Paroxysmal nocturnal haemoglobinuria treatment with pegcetacoplan
Mitapivat, a pyruvate kinase-R activator, in SCD is safe with early efficacy results
SCD LentiGlobin gene therapy: new data on VOC and ACS
Paediatric Haematology
Venetoclax + navitoclax promising for R/R ALL or LL
Nivolumab/brentuximab vedotin in R/R HL: good CMR rates
Bench-to-Bedside Science from the Presidential Symposium
Microbiome predicts B-ALL predisposition
Netrin-1 regulates haematopoietic stem cells
Unrecognised role of iron in neutrophil differentiation
Related Articles

EHA25 Highlights Podcast
SCD LentiGlobin gene therapy: new data on VOC and ACS
OS benefit in VIALE-C trial
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy